• Valemetostat (DS-3201) Research Workflows

  2026-09-11

  Learn how to deploy Valemetostat (DS-3201) in EZH2 biochemical, cellular, and translational lymphoma studies. The workflow emphasizes mutant-aware assay design, solvent control, chromatin biomarkers, and metabolic readouts inspired by a mechanistically rigorous liver-injury study.

• Candida EVs, Nrg1, and Candidemia

  2026-09-10

  The reference study identifies a concentration- and time-dependent role for Candida albicans extracellular vesicles in suppressing hyphal development through the SKO1–NRG1 regulatory axis. Its mutant, transcriptomic, clinical-isolate, and mouse-infection experiments connect vesicle cargo activity with reduced fungal virulence, while also defining important limits for translation.

• Betaine Hydrochloride in Inflammation Assays

  2026-09-10

  Use Betaine hydrochloride as a controlled assay variable, soluble buffer component, or exploratory culture supplement—not as a substitute for the oridonin intervention studied in esophageal cancer. This workflow connects rigorous reagent handling with TLR4/NF-κB/NLRP3-focused biochemical, cellular, and molecular readouts.

• PPARγ Activation in DSS-Induced Inflammatory Bowel Disease

  2026-09-09

  This study links PPARγ activation to macrophage polarization and intestinal protection in a dextran sulfate sodium model of inflammatory bowel disease. Its combined cellular and animal design supports a STAT-1/STAT-6 mechanism, while also highlighting the limits of translating acute murine findings to human disease.

• Pterostilbene Delays Dermal Fibroblast Senescence

  2026-09-09

  Zhou et al. show that pterostilbene mitigates senescence in human dermal fibroblasts by improving mitochondrial quality and promoting mitophagy. Using cellular and mouse models, the study connects mitochondrial remodeling with restored respiration, collagen preservation, and reduced senescence-associated signaling.

• Troglitazone Workflows for PPARγ and SPP1

  2026-09-08

  Use Troglitazone as a practical PPARγ agonist comparator in metabolic assays, SPP1-high macrophage screens, and renal carcinoma studies. This workflow separates established receptor pharmacology from the still exploratory question of whether PPAR modulation can reprogram tumor-associated myeloid cells.

• LBP, AMPK Mitophagy, and Muscle Atrophy

  2026-09-08

  The reference study identifies an AMPK/PINK1/Parkin-mediated mitophagy mechanism through which Lycium barbarum polysaccharide (LBP) alleviates high-fat-diet-associated skeletal muscle atrophy and metabolic dysfunction. Its combination of metabolic, mitochondrial, pharmacological, and Parkin-knockdown evidence provides a useful framework for studying sarcopenic obesity and energy metabolism regulation.

• Canagliflozin: SGLT2 Workflow Guide

  2026-09-07

  Build cleaner glucose metabolism research workflows with Canagliflozin hemihydrate while separating renal glucose reabsorption inhibition from mTOR activity. This guide combines transporter-aware assay design, practical formulation guidance, and a yeast-based counter-screen for more defensible pathway attribution.

• Chlorpromazine Workflows for CNS and Liver Studies

  2026-09-07

  Build reproducible dopamine D2 receptor, antiemetic, and cell-resolved nanoparticle assays with carefully controlled chlorpromazine exposure. This guide translates hepatic nanoparticle findings into practical experimental choices while clearly separating validated evidence from exploratory cross-domain applications.

• Sulforaphane Workflows for Stress and Chemoprevention

  2026-09-05

  Sulforaphane connects oxidative-stress biology with practical cancer and inflammation assays, from HT29 cell-cycle profiling to NLRP3-focused colitis workflows. This guide turns the compound’s Keap1-Nrf2 activity and reported anti-inflammatory effects into reproducible experimental designs, controls, and troubleshooting decisions.

• Elobixibat hydrate: IBAT Workflow Guide

  2026-09-04

  Build mechanism-led assays around Elobixibat hydrate to connect IBAT blockade with bile acid redistribution, TGR5 signaling, secretion, motility, and metabolic readouts. This guide separates clinically reported effects from practical starting conditions for cell, organoid, ex vivo, and translational workflows.

• MHY1485 Workflows for mTOR and Autophagy Studies

  2026-09-04

  MHY1485 combines mTOR pathway activation with suppression of autophagosome–lysosome fusion, making it useful for mechanistic signaling, autophagy, proliferation, and ovarian tissue workflows. This practical guide translates that profile into controlled experiments, assay choices, and troubleshooting strategies.

• Structure-Guided SARS-CoV-2 Proteomimetics

  2026-09-03

  This study converts two human ACE2 recognition elements into constrained proteomimetics that target the shallow SARS-CoV-2 Spike receptor-binding domain interface. Lead compound 28 disrupted S-RBD/hACE2 binding, inhibited pseudovirus entry, and combined epithelial stability with low permeability, supporting further investigation of localized antiviral delivery.

• Elobixibat hydrate: IBAT Assay Workflows

  2026-09-03

  Elobixibat hydrate enables mechanism-led studies of bile acid transport, intestinal motility, and downstream TGR5–GLP-1 signaling. This guide connects practical assay setup with constipation, colonoscopy preparation, and metabolic research while separating established evidence from optimization hypotheses.

• Elobixibat Hydrate: From IBAT to Colonoscopy

  2026-09-02

  Elobixibat hydrate is an ileal bile acid transporter inhibitor whose local intestinal action connects bile acid handling with motility, secretion, and colonoscopy preparation. This article interprets the E-PLUS trial protocol as a framework for selecting clinically meaningful assay endpoints rather than simply measuring laxative potency.

8139 records 2/543 page Previous Next 12345 下5页 Last page